Insulin prices in the United States: Sanofi under pressure


Reserved for subscribers

After Senator Bernie Sanders, President Joe Biden asks the French laboratory to lower its prices. This treatment, vital for diabetics, is sold there at crazy prices.





By Francois Miguet

Paul Hudson, CEO of the French pharmaceutical group Sanofi, during a general meeting of the group, in Paris, on May 3, 2022.
 © Eric Piermont/AFP

Published on


Premium Subscriber-only audio playback

I subscribe to 1€ the 1st month


DOn Sunday March 5, the President of the United States Joe Biden claimed, in a tweet, that insulin suppliers, including the French company Sanofi, significantly reduce their prices on his soil. “Last year I signed the Inflation Reduction Act to cap the cost of insulin at $35 for seniors on Medicare. [cela ne s’applique qu’aux plus de 65 ans, NDLR], and called on pharmaceutical companies to lower prices for everyone, ”wrote the tenant of the White House on the social network. The American laboratory “Eli Lilly did it, he continued. This is an important issue, and it is time for other manufacturers to follow”.




Source link -82